ABSTRACT
BACKGROUND: Cytotoxin-associated gene A (cagA) is the major virulence factor of Helicobacter pylori strains and affects the clinical outcome of patients. Blood group antigen binding adhesin (BabA) helps the strains adhere to the epithelial cell layer and is the most important adhesin of H. pylori. OBJECTIVES: We tried to study the association between the status of babA2 and cagA in H. pylori strains and histological gastritis. methods: Thirty-six patients were included. RNA was extracted from two frozen biopsy samples of the antrum and corpus, respectively, and cagA/babA2 genotypes were analyzed with reverse transcription polymerase chain reaction and direct sequencing. Two gastric specimens of the antrum and corpus, respectively, were also stained with hematoxylin and eosin to analyze H. pylori-related gastritis. RESULTS: In the antrum, 56% of the specimens were babA2 positive and in the corpus 53%. The gastritis scores of activity and inflammation were associated with the presence of babA2 in antrum specimens but not in corpus specimens. cagA gene encoding in the CagA EPIYA-D region was detected in all samples, and the sequence was completely identical between those from the gastric corpus and antrum. CONCLUSION: babA2 expression is heterogeneous and correlated with the extent of gastritis in the antrum, but not in the corpus, whereas cagA shows a monotonous genotype.
Subject(s)
Adhesins, Bacterial/genetics , Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Gastritis/microbiology , Helicobacter Infections/microbiology , Helicobacter pylori/genetics , Pyloric Antrum/microbiology , Aged , Amino Acid Sequence , Base Sequence , DNA Primers , Female , Gastritis/pathology , Genotype , Helicobacter Infections/pathology , Helicobacter pylori/isolation & purification , Helicobacter pylori/pathogenicity , Humans , Male , Middle Aged , Molecular Sequence Data , Pyloric Antrum/pathology , RNA, Bacterial/analysis , RNA, Bacterial/genetics , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
The H+/K(+)-ATPase is the dimeric enzyme responsible for H+ secretion by the gastric parietal cells. The present study examined the response of rat fundic mRNA levels of H+/K(+)-ATPase alpha-subunit and somatostatin to the inhibition of H+/K(+)-ATPase enzyme activity and gastric pH elevation by oral omeprazole administration. Omeprazole inhibits the alpha-subunit of H+/K(+)-ATPase covalently and stabilizes stimulated morphology of the parietal cell. After a single administration of omeprazole (100 mg/kg), H+/K(+)-ATPase alpha-subunit mRNA levels increased significantly by 57% at 3 h and remained elevated for 6 h, returning to the basal level by 24 h. After multiple administrations of omeprazole (100 mg/kg per day, every 24 h for 3 days), H+/K(+)-ATPase alpha-subunit mRNA levels were already elevated at the time of the last dose, reached maximum at 6 h (95% increase above control), and returned to the pre-treatment level after 36 h. Nuclear run-on assay indicated H+/K(+)-ATPase gene transcription was significantly increased by omeprazole pretreatment in vivo. In contrast, a significant decrease in fundic somatostatin mRNA occurred at 12 h after a single dose, and the inhibition was more pronounced and lasted longer after multiple doses of omeprazole. These data indicate that omeprazole, while effectively inhibiting H+/K(+)-ATPase activity, induces H+/K(+)-ATPase gene expression in the parietal cells. An inverse relationship exists between the regulation of somatostatin gene expression in fundic D-cells and H+/K(+)-ATPase gene expression. The increase in H+/K(+)-ATPase alpha-subunit mRNA could be due to alterations in extracellular gastrin/somatostatin ratios or could be induced by intracellular effects of omeprazole.
Subject(s)
Adenosine Triphosphatases/genetics , Gene Expression Regulation, Enzymologic/drug effects , Omeprazole/pharmacology , RNA, Messenger/genetics , Somatostatin/genetics , Actins/genetics , Animals , Blotting, Northern , Gastrins/blood , H(+)-K(+)-Exchanging ATPase , Hydrogen-Ion Concentration , Kinetics , Male , Radioimmunoassay , Rats , Rats, Inbred StrainsABSTRACT
AIM: : To investigate the effect of the eradication of Helicobacter pylori on histological gastritis. METHODS: : Twenty-six patients with moderate to severe atrophy received successful eradication therapy of H.pylori. Four patients dropped out and 22 were followed up prospectively for 5 years. The grades of gastritis were estimated from gastric biopsy specimens. The grade of intestinal metaplasia was also evaluated by dye-endoscopy using methylene blue (methylthioninium chloride). The serum levels of pepsinogen, gastrin and anti-parietal cell antibody were also determined. RESULTS: : The grades of atrophy decreased in patients with successful eradication therapy in the gastric corpus (before vs. 5 years after eradication, 2.09 +/- 0.15 vs. 0.91 +/- 0.17; P < 0.01) and in the antrum (2.14 +/- 0.17 vs. 1.36 +/- 0.17; P < 0.01). The levels of intestinal metaplasia were also decreased in the corpus (0.91 +/- 0.24 vs. 0.50 +/- 0.16; P < 0.05) and in the antrum (1.41 +/- 0.20 vs. 1.00 +/- 0.16; P < 0.05), which was also demonstrated by the methylene blue (methylthioninium chloride) staining method (33.4 +/- 8.2% vs. 23.0 +/- 6.5%; P < 0.05). The improvement of corpus atrophy correlated well with the high serum level of pepsinogen I (P = 0.005), but showed no correlation with the levels of anti-parietal cell antibody. CONCLUSIONS: : These results suggest that gastric atrophy and intestinal metaplasia are reversible events in some patients.
Subject(s)
Gastritis, Atrophic/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori , Intestines/pathology , Precancerous Conditions/drug therapy , Stomach Neoplasms/microbiology , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Biomarkers/blood , Drug Therapy, Combination , Female , Follow-Up Studies , Gastrins/blood , Gastritis, Atrophic/microbiology , Gastritis, Atrophic/pathology , Helicobacter Infections/complications , Humans , Male , Metaplasia/drug therapy , Metaplasia/microbiology , Metaplasia/pathology , Methylene Blue , Middle Aged , Pepsinogens/blood , Precancerous Conditions/microbiology , Precancerous Conditions/pathology , Prognosis , Prospective Studies , Stomach Neoplasms/blood , Stomach Neoplasms/pathologyABSTRACT
BACKGROUND: Hypoxia is a cause of gastric mucosal damage induced by nonsteroidal anti-inflammatory drugs (NSAIDs). The expression of hypoxia inducible factor-1alpha (HIF-1alpha) reflects the status of tissue ischaemia. AIM: To investigate the effect of NSAID administration on the expression of HIF-1alpha in human gastric mucosa. METHODS: We employed 71 patients including 14 with NSAID administration. The HIF-1alpha expression was estimated by immunohistochemistry using monoclonal antibody (H1alpha67) and raised antiserum (HI-3). Vascular endothelial growth factor expression was also examined by immunohistochemistry. HI-3 recognized hypoxia-induced protein in HeLa cells. RESULTS: In human gastric mucosa, HIF-1alpha was mainly expressed in the nuclei of the surface epithelial cells and in the neck zone both by use of HI-3 and of H1alpha67. The expression of vascular endothelial growth factor correlated well with that of HIF-1alpha. The level of HIF-1alpha in the surface epithelium was significantly higher in patients with administration of NSAIDs than those without NSAID use (P < 0.001) both in the gastric corpus and antrum. Helicobacter pylori infection did not affected the levels of HIF-1alpha. Long-term administration of rebamipide reduced the level of HIF-1alpha. CONCLUSION: HIF-1alpha expression is a new biological marker of ischaemia especially in NSAID-related gastric lesions.
Subject(s)
Alanine/analogs & derivatives , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Gastric Mucosa/metabolism , Transcription Factors/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Alanine/pharmacology , Anti-Ulcer Agents/pharmacology , Blotting, Western , Enzyme-Linked Immunosorbent Assay , Female , Humans , Hypoxia-Inducible Factor 1, alpha Subunit , Immunohistochemistry , Male , Middle Aged , Quinolones/pharmacologyABSTRACT
Omeprazole effectively suppresses acid secretion, resulting in the long-term elevation of intragastric pH and serum gastrin level. Pirenzepine has been reported to inhibit gastrin secretion. This study was carried out to examine the effects of additional pirenzepine treatment on the hypergastrinemia and gastric acid suppression induced by omeprazole. Concentrations of serum gastrin and plasma somatostatin were measured in 28 peptic ulcer patients before treatment, after omeprazole treatment (20 mg/day) for 2 weeks, and after omeprazole and pirenzepine (100 mg/day) treatment for 2 weeks. The acid inhibitory effect of pirenzepine treatment in addition to omeprazole was evaluated by 24-h intragastric pH measurement in six healthy volunteers. Serum gastrin level was increased significantly, to 2.4-fold the pretreatment level, by omeprazole treatment. Additional treatment with pirenzepine suppressed serum gastrin level to 0.6-fold the omeprazole-treatment level. The serum somatostatin level was not altered significantly either by omeprazole treatment or by omeprazole and pirenzepine treatment. In healthy volunteers whose pH 3 holding time on 24-h intragastric pH monitoring was 70% by omeprazole treatment, omeprazole and pirenzepine treatment markedly increased the pH 3 holding time, to 89%. These findings suggest that pirenzepine is useful in reducing the undesirable effects of omeprazole-induced hypergastrinemia, i.e., the excessive trophic effect of omeprazole on the acid-secreting part of the stomach and the overstimulation of acid secretion. The additional pirenzepine treatment is also effective in suppressing acid secretion.
Subject(s)
Anti-Ulcer Agents/therapeutic use , Gastric Acid/metabolism , Gastrins/blood , Omeprazole/therapeutic use , Peptic Ulcer/drug therapy , Pirenzepine/therapeutic use , Adult , Aged , Anti-Ulcer Agents/adverse effects , Drug Therapy, Combination , Duodenal Ulcer/drug therapy , Duodenal Ulcer/metabolism , Female , Humans , Hydrogen-Ion Concentration , Male , Middle Aged , Omeprazole/adverse effects , Peptic Ulcer/metabolism , Radioimmunoassay , Somatostatin/blood , Stomach Ulcer/drug therapy , Stomach Ulcer/metabolismABSTRACT
Clinicopathologic characteristics of 92 colorectal laterally spreading tumors (LST) endoscopically or surgically resected were examined. Lesions were macroscopically classified into two categories according to their surface structure :(1) granular type (G type, 47 lesions), (2) flat type (F type, 45 lesions). The size (maximum diameter) of G type lesions was 24.7 +/- 11.3 mm (Mean +/- SD) and that of F type lesions was 14.2 +/- 7.4 mm. The size of G type lesions was significantly larger than that of F type lesions (p < 0.01). Among G type lesions, cancerous lesion was present in 2 (25.0%) of 8 lesions 10-14 mm in diameter, 2 (22.2%) of 9 lesions 15-19 mm in diameter and 19 (63.3%) of 30 lesions more than 20mm in diameter. Regarding F type lesions, cancerous lesion was present in 15 (46.9%) of 32 lesions 10-14 mm in diameter, 4 (80.0%) of 5 lesions 15-19 mm in diameter and 8 (100%) of 8 lesions more than 20mm in diameter. The incidence of carcinoma in F type lesions was higher than that in G type lesions irrespective of size. F type lesions with carcinoma showed a trend toward a higher frequency of submucosal invasion and F type lesions with adenoma revealed tendency of showing severe atypia in comparison with G type lesions. The adenomatous component of LST showed a tubulo-villous architecture in 13 (28.3%) of 46 G type lesions, however none of F type lesions had a tubulo-villous component. These results indicated that clinicopathologic characteristics of F type are obviously different from G type. Furthermore, F type had a higher malignant potential than G type and is thought to have a more important role as a precursor of colorectal carcinoma than G type.
Subject(s)
Adenocarcinoma/pathology , Colorectal Neoplasms/pathology , Adenocarcinoma/surgery , Aged , Colonoscopy , Colorectal Neoplasms/surgery , Endoscopy , Female , Humans , Intestinal Mucosa/surgery , Male , Middle Aged , Neoplasm InvasivenessABSTRACT
We analyzed 66 cases (47 males and 19 females) of Crohn's disease at Hiroshima University hospital from September 1975 to October 1994 to clarify the course and prognosis of Crohn's disease. The age at onset was 21.1 +/- 7.3 years old (mean +/- SD), terms between onset and diagnosis were 21.5 +/- 33.0 months (mean +/- SD) and observation period was 65.5 +/- 44.6 months (mean +/- SD). Sites of lesion were 18 ileum, 41 ileocolon and 7 colon. Thirty-one cases, 20 cases of which had intestinal obstruction, underwent surgical operation (12 ileum types, 18 ileocolic types, 1 colon type). The cumulative probability of surgery at one, five and ten years after onset of symptoms were 12.1%, 28.8% and 56.9%, respectively. As for cumulative probability of surgical operation at one, five and ten years after diagnosis were 25.8%, 36.7% and 74.4%, respectively. Results of the cumulative probability of surgery by anatomical involvement indicated that the ileum type had a statistically significantly higher risk than other types. In each analysis compliance to nutritional therapy was also an important prognostic factor. Overall, our results indicated that the site of lesion and the compliance to nutritional therapy were important factors which have an effect on the course and prognosis of Crohn's disease patients.
Subject(s)
Crohn Disease , Adolescent , Adult , Age of Onset , Child , Crohn Disease/physiopathology , Crohn Disease/surgery , Crohn Disease/therapy , Female , Follow-Up Studies , Humans , Male , Nutritional Support , PrognosisSubject(s)
Lupus Erythematosus, Systemic/complications , Protein-Losing Enteropathies/etiology , Adult , Anti-Inflammatory Agents/administration & dosage , Female , Humans , Methylprednisolone/administration & dosage , Protein-Losing Enteropathies/diagnosis , Protein-Losing Enteropathies/drug therapy , Serum Albumin/deficiencyABSTRACT
Antral gastrin and somatostatin gene expression during starvation and after refeeding with liquid meals of varying composition were studied. Northern and slot-blot hybridization analyses showed that starvation caused a marked decrease in antral gastrin messenger RNA (mRNA) level by 12 hours associated with an increase in somatostatin mRNA. After 48 hours of fasting, antral gastrin mRNA was 26% and somatostatin mRNA was 136% of their prefasting levels. Refeeding caused increased 2-hour integrated gastrin mRNA levels after liquid peptone (+45%), phenylalanine (+31%), and olive oil (+13%), but no changes were observed with glucose or saline solutions. Integrated 2-hour immunoreactive antral gastrin content was increased after peptone (+106%), phenylalanine (+68%), and olive oil (+32%) meals but was not increased after glucose (-11%) or saline (-10%). In some cases, both gastrin mRNA and peptide responses could be measured as early as 15 minutes. The same nutrients that increased gastrin mRNA levels caused decreased 2-hour integrated somatostatin mRNA levels; peptone (-30%), phenylalanine (-28%), and olive oil (-21%), but neither glucose nor saline, altered somatostatin mRNA levels. These results suggest that antral gastrin and somatostatin genes were regulated in opposite directions, in a coordinate manner, by specific gastric nutrients that stimulate gastrin release.
Subject(s)
Gastrins/genetics , Gene Expression Regulation , Pyloric Antrum/metabolism , Somatostatin/genetics , Starvation , Animals , Food , Gastrins/analysis , Gastrins/biosynthesis , Gastrins/metabolism , Male , Peptides/analysis , Pyloric Antrum/chemistry , RNA, Messenger/analysis , Rats , Rats, Inbred Strains , Somatostatin/analysis , Somatostatin/biosynthesisABSTRACT
We examined the effects of gastrin and histamine on rat gastric H+/K(+)-ATPase, the enzyme responsible for H+ secretion, gene expression in vivo. Gastrin 17 (G 17) or histamine dihydrochloride (histamine) was continuously infused through the femoral vein of anesthetized rats. Gastric H+/K(+)-ATPase mRNA levels were measured using northern blot analysis. Infusion of G 17 and histamine increased the H+/K(+)-ATPase mRNA level significantly compared with basal control level or vehicle control level (P < 0.01). However, pretreatment with famotidine, a potent histamine-2 (H2)-receptor antagonist, inhibited the increase of rat gastric H+/K(+)-ATPase mRNA following G 17 and histamine infusion. These findings indicate that both histamine and G 17 increase expression of H+/K(+)-ATPase mRNA by activating H2 receptor on the parietal cell.
Subject(s)
Famotidine/pharmacology , Gastrins/pharmacology , H(+)-K(+)-Exchanging ATPase/biosynthesis , Histamine H2 Antagonists/pharmacology , Histamine/pharmacology , Hormones/pharmacology , Parietal Cells, Gastric/enzymology , Receptors, Histamine H2/physiology , Actins/biosynthesis , Actins/genetics , Animals , Blotting, Northern , Gene Expression/drug effects , H(+)-K(+)-Exchanging ATPase/genetics , Infusions, Intravenous , Male , Parietal Cells, Gastric/drug effects , Premedication , RNA, Messenger/genetics , Rats , Rats, WistarABSTRACT
The REV1 protein is a member of the growing family of translesion DNA polymerases. A cDNA of the human REV1 gene that we had originally isolated encoded 1250 amino acids residues, which was one amino acid shorter than previously reported ones. The shorter form of REV1 was named REV1S. All individuals examined expressed equivalent amounts of REV1S and REV1 mRNA, suggesting that the REV1S mRNA is a splicing variant. We show that the REV1S protein also possesses deoxycytidyl transferase activity that inserts a dCMP opposite a DNA template apurinic/apyrimidinic site. Deletion and point mutation analysis of the REV1S protein revealed that the domain required for deoxycytidyl transferase and DNA binding activities of the REV1S protein are located in a conserved domain of translesion DNA polymerases. This result indicates that the structure of the catalytic site of the deoxycytidyl transferase closely resembles that of the translesion DNA polymerases. Therefore, the molecular mechanism of the dCMP transfer reaction of the REV1S protein and maybe also the REV1 protein might be the same as that of the dNTP transfer reaction of the translesion DNA polymerases.
Subject(s)
Fungal Proteins/metabolism , Nucleotidyltransferases/metabolism , Saccharomyces cerevisiae Proteins , Amino Acid Sequence , Base Sequence , Catalysis , Cloning, Molecular , DNA Primers , DNA, Complementary , DNA-Directed DNA Polymerase/metabolism , Fungal Proteins/chemistry , Fungal Proteins/genetics , Humans , Molecular Sequence Data , Nuclear Proteins , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
OBJECTIVES: We investigated the effects of short-term administration of omeprazole on the regulation of antral gastrin and somatostatin in 15 healthy men. METHODS: Seven of these men were administrated 20 mg, and eight were given 40 mg of omeprazole for 8 days each. All subjects were examined before the first dose and after the last dose. RESULTS: Each dose significantly increased the basal serum gastrin level. Although the dose of omeprazole 20 mg/day had no significant affect on the antral somatostatin content, omeprazole 40 mg/day increased the antral gastrin content and decreased the antral somatostatin content significantly. Both doses significantly increased in the antral gastrin mRNA level. However, neither dose significantly affected the antral somatostatin mRNA level. CONCLUSIONS: This study shows reciprocal changes between the antral content of gastrin and somatostatin following omeprazole administration. These results indicate that antral somatostatin may be involved in the hypersecretion of gastrin produced by omeprazole in humans.
Subject(s)
Gastric Mucosa/metabolism , Gastrins/metabolism , Omeprazole/pharmacology , Somatostatin/metabolism , Adult , Dose-Response Relationship, Drug , Gastric Mucosa/drug effects , Gastrins/blood , Humans , Immunoblotting , Male , Omeprazole/adverse effects , Pyloric Antrum/chemistry , RNA, Messenger/analysis , Radioimmunoassay , Somatostatin/blood , Stomach/drug effectsABSTRACT
BACKGROUND: Recent studies on the role of Helicobacter pylori in the pathogenesis of duodenal ulcers have focused on the mechanism by which H. pylori infections cause exaggerated gastrin release. METHODS: We determined meal-stimulated serum gastrin concentrations and antral somatostatin content in 24 asymptomatic volunteers (6 H. pylori-infected, 18 H. pylori-uninfected). Somatostatin content was determined by radioimmunoassay in biopsy specimens obtained from the antrum. RESULTS: Fasting and integrated 2-h gastrin concentrations were significantly higher in H. pylori-positive volunteers than in H. pylori-negative volunteers (fasting, 111 +/- 16.3 pmol/l versus 53.4 +/- 3.5 pmol/l; p < 0.05; integrated 2-h, 267 +/- 41.2 pmol/l versus 70.1 +/- 2.1 pmol/l; p < 0.01). Antral somatostatin content was 0.764 +/- 0.173 ng/mg and 2.931 +/- 0.414 ng/mg in H. pylori-positive and -negative volunteers, respectively (p < 0.01). CONCLUSIONS: Low antral somatostatin content may cause hypergastrinemia in asymptomatic healthy volunteers, and H. pylori may contribute to the pathogenesis of duodenal ulcer, through this mechanism.
Subject(s)
Gastrins/biosynthesis , Helicobacter Infections/metabolism , Helicobacter pylori/pathogenicity , Pyloric Antrum/metabolism , Somatostatin/biosynthesis , Adult , Biopsy , Duodenal Ulcer/metabolism , Duodenal Ulcer/microbiology , Gastrins/blood , Gastroscopy , Helicobacter Infections/pathology , Helicobacter Infections/physiopathology , Humans , Male , Pyloric Antrum/microbiology , Pyloric Antrum/pathology , Radioimmunoassay , Somatostatin/analysisABSTRACT
Mutations of the p53 tumor suppressor gene are the most prevalent genetic alteration observed in a wide variety of human cancers. In this study we examined 63 methylcholanthrene (MCA)-induced sarcomas from C57BL/6N x C3H/HeN F1 (BCF1) or C3H/HeN x C57BL/6N F1 (CBF1) mice for p53 gene mutations and loss of heterozygosity (LOH) of chromosome 11. Mutation analysis was done on exons 5 to 8 of the p53 gene by polymerase chain reaction-single strand conformation polymorphism analysis. This identified 53 potential mutations in 45 sarcomas. Mutations were further confirmed by direct sequencing of the region. Forty-nine of the 53 cases (94%) were missense mutations, while the rest included two nonsense mutations, one silent mutation and one insertional mutation. Spectra of base substitutions were: 25 cases (47%) of G:C-->T:A transversion, 13 cases (25%) of G:C-->A:T transition (CpG site 15%), 13 cases (24%) of G:C-->C:G transversion, a case (2%) of A:T-->T:A transversion and a case (2%) of insertion. In addition, analysis of 5 polymorphic markers of mouse chromosome 11 revealed LOH in ten cases (22%) among those carrying p53 mutations. In nine of these 10 cases, the loss involved all 5 markers. In addition, the loss was biased toward the C57BL allele (9 cases). The present study establishes the pattern of mutation of the p53 gene in MCA-induced mouse sarcomas.
Subject(s)
Genes, p53 , Loss of Heterozygosity , Mutation , Sarcoma, Experimental/genetics , Amino Acid Sequence , Animals , Humans , Methylcholanthrene , Mice , Mice, Inbred Strains , Molecular Sequence Data , Point Mutation , Sarcoma, Experimental/chemically induced , Sequence AlignmentABSTRACT
Pirenzepine has inhibitory effects on gastrin secretion both in vivo and in vitro. The aim of this study was to determine the mechanism responsible for the suppression of omeprazole-induced hypergastrinemia that occurs with pirenzepine treatment. The effects were measured in rats treated with oral omeprazole plus intraperitoneal pirenzepine or saline once daily for seven days in the antrum. The serum gastrin level increased significantly by more than sixfold with omeprazole treatment; additional treatment with pirenzepine suppressed this increase by 48%. Pirenzepine treatment did not change the level of gastrin mRNA but significantly increased the level of somatostatin mRNA. Combination treatment with omeprazole plus pirenzepine significantly decreased the gastrin mRNA level to half and significantly increased the somatostatin mRNA level up to 1.4-fold of the levels achieved with omeprazole treatment alone. These results suggest that the stimulatory effect of omeprazole on gastrin synthesis is partially blocked by pirenzepine via mediation of somatostatin synthesis in the antrum.
Subject(s)
Anti-Ulcer Agents/pharmacology , Gastrins/blood , Gene Expression Regulation/drug effects , Omeprazole/pharmacology , Pirenzepine/pharmacology , Actins/metabolism , Administration, Oral , Animals , Blotting, Northern , Gastric Acid/metabolism , Gastrins/genetics , Injections, Intraperitoneal , Male , Omeprazole/administration & dosage , Pirenzepine/administration & dosage , RNA, Messenger/analysis , Radioimmunoassay , Rats , Rats, Wistar , Somatostatin/blood , Somatostatin/geneticsABSTRACT
We examined the role of capsaicin-sensitive afferent neurons in pH-dependent gastrin secretion in the rat stomach. The change in serum gastrin levels relative to changes in luminal pH (using omeprazole for luminal alkalization or 0.1 N HCl for luminal acidification) was studied after oral administration of 4% lidocaine or capsaicin-induced ablation of afferent neurons. The increase of serum gastrin levels by luminal alkalization was significantly inhibited (50%) after administration of 4% lidocaine. Capsaicin pretreatment (125 mg/kg subcutaneously over two days) inhibited the change in serum gastrin levels both the luminal alkalization (38%) and acidification (66%). Antral gastrin contents, somatostatin contents, gastrin mRNA expression, and somatostatin mRNA expression were not significantly affected by capsaicin pretreatment. Our results indicate that capsaicin-sensitive afferent neurons participate in the secretion of gastrin by luminal alkalization and inhibition of gastrin by luminal acidification.
Subject(s)
Acids/pharmacology , Alkalies/pharmacology , Gastrins/metabolism , Hydrogen/metabolism , Neurons, Afferent/drug effects , Neurons, Afferent/physiology , Anesthetics, Local/pharmacology , Animals , Capsaicin/pharmacology , Gastrins/blood , Gastrins/genetics , Hydrogen-Ion Concentration , Lidocaine/pharmacology , Male , Pyloric Antrum/metabolism , RNA, Messenger/metabolism , Rats , Rats, Wistar , Somatostatin/genetics , Somatostatin/metabolismABSTRACT
We investigated an antiinflammatory effect of rebamipide [2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid], a gastroprotective agent, in H. pylori-associated gastritis. Eighty-six patients with H. pylori-positive chronic gastritis were enrolled: 53 were treated with rebamipide (300 mg daily for 12 months) and 33 served as controls. Significant decreases in mononuclear cell infiltration into the antrum and corpus were noted in the rebamipide treatment group (before vs after, 1.42 +/- 0.15 vs 1.02 +/- 0.15; P < 0.01 and 1.60 +/- 0.15 vs 1.21 +/- 0.14; P < 0.05, respectively). Levels of infiltrating neutrophil were also decreased in the antrum (before vs after, 0.98 +/- 0.14 vs 0.70 +/- 0.13; P < 0.05) and were associated with a decrease in iNOS production. Sera from patients treated with rebamipide showed a significant decrease in gastrin (276.3 +/- 58.3 pg/ml vs 173.0 +/- 34.2 pg/ml; P < 0.05), whereas no change was observed in the control group. These suggest that long-term rebamipide treatment improved histologic gastritis and decreased serum gastrin levels in H. pylori-associated gastritis.
Subject(s)
Alanine/analogs & derivatives , Alanine/administration & dosage , Anti-Ulcer Agents/administration & dosage , Gastritis/drug therapy , Gastritis/microbiology , Helicobacter Infections , Helicobacter pylori , Quinolones/administration & dosage , Alanine/therapeutic use , Anti-Ulcer Agents/therapeutic use , Drug Administration Schedule , Gastrins/blood , Gastritis/metabolism , Gastritis/pathology , Humans , Nitric Oxide Synthase/biosynthesis , Nitric Oxide Synthase Type II , Pepsinogens/blood , Quinolones/therapeutic use , Stomach/drug effects , Stomach/enzymology , Stomach/pathologyABSTRACT
The aim of this study was to investigate whether gastrin regulates morphological changes and alpha-subunit gene expression in parietal cells through the gastrin/CCK-B receptor on enterochromaffin-like cells by histamine release. Treatment with 100 mg/kg of YM022, a potent and selective gastrin/CCK-B receptor antagonist, for one week in rats did not alter mRNA levels of histidine decarboxylase or H+, K+-ATPase. However, parietal cell morphology predominantly changed to the resting form, although the serum gastrin concentration was significantly increased. Additional treatment with YM022 and oral omeprazole, 100 mg/kg, for one week markedly suppressed the increases of mRNA levels of histidine decarboxylase and H+, K+-ATPase and completely blocked the morphological transformation of the parietal cells to a stimulated form induced by treatment with omeprazole alone. This indicates that the morphological transformation of parietal cells to an activated form with a subsequent increase in H+, K+-ATPase synthesis caused by hypergastrinemia is mediated by increased histidine decarboxylase gene expression in enterochromaffin-like cells via gastrin/CCK-B receptors.
Subject(s)
Gastric Acid/metabolism , Gastrins/physiology , Parietal Cells, Gastric/drug effects , Receptors, Cholecystokinin/physiology , Actins/biosynthesis , Animals , Benzodiazepines/pharmacology , Enzyme Inhibitors/pharmacology , Gastrins/blood , Gene Expression , H(+)-K(+)-Exchanging ATPase/biosynthesis , Histamine Release , Histidine Decarboxylase/antagonists & inhibitors , Histidine Decarboxylase/biosynthesis , Hormone Antagonists/pharmacology , Male , Omeprazole/pharmacology , Proton Pump Inhibitors , RNA, Messenger/genetics , Rats , Rats, Wistar , Receptors, Cholecystokinin/antagonists & inhibitorsABSTRACT
BACKGROUND: Helicobacter pylori infection is considered a risk factor for gastric carcinoma. However, the effect of eradication therapy in gastric carcinoma patients is not well known. The aim of this study was to investigate the relationship between H. pylori infection and tumor growth of gastric carcinoma. METHODS: Fifty-one patients with gastric carcinoma participated in the study. Thirty-three were H. pylori-positive, 6 were H. pylori-negative, and 12 were diagnosed with gastric carcinoma after eradication of H. pylori. To investigate tumor growth of gastric carcinoma, cell proliferation and angiogenesis of the tumors were evaluated by immunohistochemical techniques using Ki-67 and CD34. RESULTS: The Ki-67 labeling index was 47.9 +/- 2.6 (mean +/- s) in the H. pylori-positive group, 38.1 +/- 3.6 in the H. pylori-eradicated group, and 22.2 +/- 5.5 in the H. pylori-negative group. It was significantly lower in the H. pylori-eradicated and H. pylori-negative groups than in the H. pylori-positive one, and a significant difference was also found between the H. pylori-positive and H. pylori-eradicated groups. The microvessel counts were 62.5 +/- 3.0, 50.2 +/- 4.0, and 66.0 +/- 9.8 in the positive, eradicated, and negative groups, respectively. A significant difference was found between the H. pylori-positive and H. pylori-eradicated groups. CONCLUSION: Our results suggest that H. pylori infection is associated with cell proliferation, and its eradication may influence tumor vascularity of gastric carcinoma. Therefore, H. pylori eradication therapy may contribute to the suppression of tumor growth.